Last reviewed · How we verify

Saccharomyces boulardi (Sb)

Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · FDA-approved active Small molecule

Saccharomyces boulardii is a live probiotic yeast that restores healthy gut microbiota and strengthens intestinal barrier function.

Saccharomyces boulardii is a live probiotic yeast that restores healthy gut microbiota and strengthens intestinal barrier function. Used for Acute diarrhea in children, Antibiotic-associated diarrhea, Traveler's diarrhea prevention and treatment.

At a glance

Generic nameSaccharomyces boulardi (Sb)
SponsorFundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan
Drug classProbiotic
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

S. boulardii colonizes the gastrointestinal tract and produces metabolites that inhibit pathogenic bacteria, reduce intestinal permeability, and modulate local immune responses. It also produces antimicrobial compounds and competes with harmful organisms for nutrients and adhesion sites on the intestinal epithelium.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: